1380100-86-6 Usage
Uses
Used in Pharmaceutical Industry:
(S)-4-fluoro-N-(1-(3-hydroxyazetidin-1-yl)-3-methylbutan-2-yl)-N,3-dimethylbenzamide is used as a potential pharmaceutical agent for its unique molecular structure that allows for interactions with biological systems. The presence of the azetidine ring and the fluorine atom may contribute to its effectiveness in treating specific medical conditions, although further research is necessary to determine its exact applications and therapeutic potential.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (S)-4-fluoro-N-(1-(3-hydroxyazetidin-1-yl)-3-methylbutan-2-yl)-N,3-dimethylbenzamide serves as a valuable compound for studying its interactions with biological systems. Its chiral nature and the presence of key functional groups make it an interesting subject for exploring new drug development pathways and understanding its potential impact on various medical conditions.
Used in Drug Design and Development:
(S)-4-fluoro-N-(1-(3-hydroxyazetidin-1-yl)-3-methylbutan-2-yl)-N,3-dimethylbenzamide is utilized in drug design and development due to its unique molecular architecture. (S)-4-fluoro-N-(1-(3-hydroxyazetidin-1-yl)-3-methylbutan-2-yl)-N,3-dimethylbenzamide's potential to interact with biological targets makes it a promising candidate for the creation of new therapeutic agents, pending further investigation into its pharmacological properties and safety profile.
Check Digit Verification of cas no
The CAS Registry Mumber 1380100-86-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,0,1,0 and 0 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1380100-86:
(9*1)+(8*3)+(7*8)+(6*0)+(5*1)+(4*0)+(3*0)+(2*8)+(1*6)=116
116 % 10 = 6
So 1380100-86-6 is a valid CAS Registry Number.
1380100-86-6Relevant academic research and scientific papers
NEW IKACH BLOCKERS
-
Page/Page column 95-96, (2012/06/16)
The invention relates to compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, x and y are as defined herein. Compounds according to Formula (I) are pharmacologically effective as potassium channel inhibitors, in particular inhibitors of the acetylcholine operated inward rectifying potassium channel current (i.e. IKACh blockers), and are believed to be useful in the treatment of cardiac arrhythmias, in particular supraventricular tacharrhythmias, such as atrial fibrillation and atrial flutter.
